ArticleClinicoEconomics and outcomes research : CEOR2015
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain.
Josep Darbà et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this paperpooled itcites it